興科蓉醫藥(6833.HK)簽訂德美醫療美容機構收購項目 加碼醫美賽道 完善醫美業務結構
興科蓉醫藥控股有限公司(「興科蓉醫藥」或「本公司」，連同其附屬公司，統稱「本集團」，股份代號：6833)欣然宣佈，(交易時段後)正式簽訂收購德美醫療美容機構的股權併購協議。此次收購是延續公司1月20日公吿的合作意向協議，於此基礎上雙方達成的進一步的合作。
德美醫療美容主要業務為提供醫療美容服務，屬於醫美行業的下游服務行業。業務特色是以提取自體脂肪為填充物進行整形手術，且專注自體脂肪移植整形已超過20年，其技術應用為行業領先水平，為全國第一家將脂肪移植技術分化應用在輪廓打造、塑形和抗衰等項目，也是唯一一家用自體脂肪修復凹陷性疤痕的整形機構。
隨着醫美市場逐步規範，同時進入醫美領域的門坎也將逐步提高，合規化經營的機構和產品也將逐步引領市場。根據本集團佈局醫美賽道的發展策略，其目標是打造集醫美原料，產品研發，生產，銷售及終端醫美機構相互配合的全產業鏈。此次完成對德美醫療美容的收購項目，象徵着本集團在醫美終端建立了第一家美容醫療醫院，這對於公司完善醫美業務結構具有重大意義。本集團將憑藉德美醫療美容的綜合性服務功能，將打造一個為集團醫美產品進行測試、試用、展示推廣、客户體驗以及研發產品與醫美整形配合使用方案設計等的醫美終端多功能中心。同時，公司藉此建立自己的醫美服務品牌和隊伍，對公司研發產品在終端的注射使用進行技術培訓，以及產品宣傳推廣。
興科蓉醫藥控股有限公司董事會表示：「此次完成收購德美醫療美容，進一步拓展醫美行業下游業務，是公司持續完善醫美產業鏈的戰略佈局的體現，也意味着公司已經逐步建立了完善的醫美產品研發業務和醫美終端醫療結構業務。從公司業務角度來看，本次收購目標及其網絡可為後續營銷及銷售公司藥品及醫療美容產品帶來協同效益。從未來的業務發展方向來看，興科蓉醫藥將逐步建立藥品及醫療美容產品兩個業務分部，雙賽道並駕齊驅是公司目前的重點發展戰略,後續的增長空間和增速都值得期待。」
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
